Alpelisib, in combination with Fulvestrant, an ER antagonist, is now FDA-approved for patients PIK3CA-mutated, HR-positive, HER2- negative BC after endocrine therapy-based treatments or with disease progression (42). The gene discussed is ERBB2; the disease is breast cancer.